About Us
Aradigm is on a mission to create sustainable, affordable access to life-saving medicines through a novel financial and delivery model that brings together every stakeholder — payers, providers, manufacturers, and, most importantly, patients.
Our Story
Aradigm was founded to solve one of healthcare’s most urgent and complex challenges: ensuring sustainable access to the next generation of transformative therapies—cell and gene therapies (CGTs).
Treatments are now available that can prevent or cure diseases that have historically caused enormous suffering and mortality, by targeting the genetic or cellular causes of the disease. However, as treatments become increasingly transformative—and costly—traditional systems for payment and delivery haven’t kept pace.
We built Aradigm as a public benefit corporation to foster sustainable access to transformative therapies with an entirely pass-through business model. We partner with employers, payers, providers, and manufacturers to deliver a novel, trustworthy, and comprehensive model—essential to shift the paradigm in delivering breakthrough therapies.
Our Mission
To unlock access to transformative therapies through collaborative, incentive-aligned financial and clinical infrastructure that benefits patients and all stakeholders involved in their care.
Our Team
Our team brings deep experience across care delivery, insurance, pharma, and patient engagement — and we’re applying it to solve healthcare’s most complex challenges with integrity, transparency, and lasting impact.
-
Will Shrank, M.D.
-
Spencer Carrucciu
-
Annie Collins
-
Justus Ruff
-
Alec Kingston
-
Jack Larkin
Our Advisory Board
-
Willis Chandler
-
Ginny Proestakes
-
Denny Weinberg
-
Steve Pearson
-
Chronis Manolis
-
William Flemming
-
Hannah Katch
-
Tay Salimullah
Message from the CEO
“The science is advancing every day — bringing us transformative therapies that can cure or prevent some of the most debilitating and intractable diseases. But the fragmented way we pay for care today stands in the way. To ensure affordable access, we face a clear choice: if we hope to deliver these therapies sustainably, we must change how they’re paid for and delivered. At Aradigm, we’re catalyzing that change.”
Will Shrank
